RxDoctor Payments Data

Siby Ayalloore, MD

Advanced Heart Failure and Transplant Cardiology · Opelousas, LANPI 1891985081

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (52.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 48 manufacturers reported payments, led by AstraZeneca at 37.2% of the total.

$44,691in general payments, 2019–2025

Across 637 payments — averaging $70.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$17K
  • Boehringer Ingelheim$8K
  • Boston Scientific$3K
  • Medtronic$3K
  • Abbott$2K
  • Merck$1K
  • plus $11K from 42 others
$873,861in research payments, 2019–2025

Across 73 payments — averaging $11,971 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$742K
  • Merck$83K
  • Abbott$27K
  • Alnylam Pharmaceuticals Inc.$15K
  • Vifor (international) Ltd.$8K

What the payments were for

  • Speaking & faculty fees$23,30552%
  • Travel & lodging$6,11314%
  • Food & beverage$15,23434%
  • Education$390%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,138,944
Medicare patients
1,298
Services billed
11,600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis48$1,079,842
EntrestoSacubitril/Valsartan845$702,748
EliquisApixaban791$582,105
XareltoRivaroxaban670$495,944
JardianceEmpagliflozin330$268,451
FarxigaDapagliflozin Propanediol324$242,212
OzempicSemaglutide109$128,737
Repatha SureclickEvolocumab122$81,835
RybelsusSemaglutide35$36,894
WegovySemaglutide26$35,022
VascepaIcosapent Ethyl68$32,518
NexlizetBempedoic Acid/Ezetimibe57$29,978
MultaqDronedarone Hcl14$18,599
DapagliflozinDapagliflozin Propanediol28$16,807
NexletolBempedoic Acid28$15,419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$1,223$1,661,947839 claims
NovartisEntresto$1,144$702,748845 claims
Johnson & JohnsonXarelto$628$495,944670 claims
Boehringer IngelheimJardiance$7,725$268,451330 claims
AstraZenecaFarxiga, Brilinta$16,607$253,093349 claims
Novo NordiskOzempic, Rybelsus, Wegovy$281$200,653170 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$305$45,39885 claims
Sanofi-aventis U.S. LLCMultaq$14$18,59914 claims
Lilly USA, LLCTrulicity$1,338$13,89515 claims
MerckVerquvo$1,390$7,87612 claims
AmgenCorlanor$186$5,71312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Louisianaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Opelousas

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →